Trial Profile

Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Dec 2024 Results presented in the Mitsubishi Tanabe Pharma Corporation Media Release.
27 Dec 2024 According to a Mitsubishi Tanabe Pharma Corporation media release, based on data from this trial the Eli Lilly Japan received manufacturing and marketing authorization in Japan from the Japanese Ministry of Health, Labour and Welfare (MHLW) for Zepbound (non-proprietary name: tirzepatide; hereinafter referred to as Zepbound, a long-acting GIP/GLP-1 receptor agonist, for the treatment of the chronic disease of obesity disease with multiple factors.
07 Aug 2023 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com